SignalXSignalX

COGT Cogent Biosciences, Inc.

Q3 2025 10-Q
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Cogent Biosciences, Inc. Overview

Cogent Biosciences, Inc. (COGT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New financing risk due to $400M Credit Facility with SLR, $75M tranche contingent on positive Phase 3 PEAK data
  • • Updated covenant risk includes restrictive terms limiting operations, acquisitions, and licensing under Loan and Security Agreement
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$81M

ROE

-26.8%

Total Assets

$426M

Source: XBRL data from Cogent Biosciences, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Cogent Biosciences, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.